107 related articles for article (PubMed ID: 8703821)
1. Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs.
Philpott NJ; Elebute MO; Powles R; Treleaven JG; Gore M; Dainton MG; Min T; Swansbury GJ; Catovsky D
Br J Haematol; 1996 Jun; 93(4):884-7. PubMed ID: 8703821
[TBL] [Abstract][Full Text] [Related]
2. Risk of leukemia after platinum-based chemotherapy for ovarian cancer.
Travis LB; Holowaty EJ; Bergfeldt K; Lynch CF; Kohler BA; Wiklund T; Curtis RE; Hall P; Andersson M; Pukkala E; Sturgeon J; Stovall M
N Engl J Med; 1999 Feb; 340(5):351-7. PubMed ID: 9929525
[TBL] [Abstract][Full Text] [Related]
3. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
5. Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB.
Griesinger F; Metz M; Trümper L; Schulz T; Haase D
Lung Cancer; 2004 May; 44(2):261-5. PubMed ID: 15084391
[TBL] [Abstract][Full Text] [Related]
6. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Dissing M; Le Beau MM; Pedersen-Bjergaard J
J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
[No Abstract] [Full Text] [Related]
9. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia.
Zompi S; Viguié F
Leuk Lymphoma; 2002 Feb; 43(2):275-80. PubMed ID: 11999558
[TBL] [Abstract][Full Text] [Related]
11. [Hypomagnesemic and hypocalcemic coma, convulsions and ocular motility disorders after chemotherapy with platinum compounds].
Bachmeyer C; Decroix Y; Médioni J; Dhôte R; Benfiguig K; Houillier P; Grateau G
Rev Med Interne; 1996; 17(6):467-9. PubMed ID: 8758533
[TBL] [Abstract][Full Text] [Related]
12. [Therapy-related myeloid leukemia following platinum-based chemotherapy for ovarian cancer].
Shimura K; Shimazaki C; Okano A; Hatsuse M; Okamoto A; Takahashi R; Hirai H; Sumikuma T; Ashihara E; Inaba T; Fujita N; Yasuda J; Nakagawa M
Rinsho Ketsueki; 2001 Feb; 42(2):99-103. PubMed ID: 11280924
[TBL] [Abstract][Full Text] [Related]
13. The incidence of secondary leukemias.
Leone G; Mele L; Pulsoni A; Equitani F; Pagano L
Haematologica; 1999 Oct; 84(10):937-45. PubMed ID: 10509043
[TBL] [Abstract][Full Text] [Related]
14. Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
Smith MA; Rubinstein L; Cazenave L; Ungerleider RS; Maurer HM; Heyn R; Khan FM; Gehan E
J Natl Cancer Inst; 1993 Apr; 85(7):554-8. PubMed ID: 8455202
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.
Stewart L;
Cochrane Database Syst Rev; 2000; (2):CD001418. PubMed ID: 10796788
[TBL] [Abstract][Full Text] [Related]
16. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K
Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831
[TBL] [Abstract][Full Text] [Related]
17. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
18. Secondary myelodysplasia and acute leukemia following carboplatin-containing combination chemotherapy for ovarian cancer.
Colon-Otero G; Malkasian GD; Edmonson JH
J Natl Cancer Inst; 1993 Nov; 85(22):1858-60. PubMed ID: 8230267
[No Abstract] [Full Text] [Related]
19. Platinum compounds and therapy related acute promyelocytic leukemia.
Martin J; Majumdar G
Hematol J; 2002; 3(6):321-3. PubMed ID: 12522457
[TBL] [Abstract][Full Text] [Related]
20. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
